Therefore, the purpose of this study was to determine the incidence of and the risk factors for depression in patients with Graves’ disease who developed SCH after 131I treatment, and to evaluate the therapeutic effect of thyroid hormone replacement in these patients. This evidence concerns the gene TG and depressive symptom measurement.